SCHEMBL5801389

SCHEMBL5801389

O=C(Nc1cccc2c1C(=O)NC2O)c1ccc(Cl)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.49
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 6/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
STK33 Q9BYT3 1/20 0.43
KMT2A Q03164 9/20 0.41
NPC1 O15118 7/20 0.41
RAB9A P51151 7/20 0.41
MEN1 O00255 8/20 0.41
TSHR P16473 1/20 0.41
PRSS12 P56730 2/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5800325 0.81 ALDH1A1 (0.49) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL3379082 0.77 KDM4E (0.58) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL18652100 0.75 ALDH1A1 (0.54) HPGDALDH1A1KDM4ECASP3
SCHEMBL23934282 0.75 KDM4E (0.59) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL5781754 0.75 HPGD (0.50) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL3380643 0.73 HPGD (0.53) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL3377662 0.71 HPGD (0.44) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL5782094 0.70 ALDH1A1 (0.50) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL3381006 0.69 F10 (0.45) HPGDALDH1A1SMN1; SMN2KDM4ENPSR1
SCHEMBL5780260 0.69 HPGD (0.41) HPGDALDH1A1SMN1; SMN2KDM4ESTK33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408962-B1 SUBSTITUTED ISOINDOLES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2006-03-15 EP disclosed
US-6933295-B2 Substituted isoindoles and the use thereof BAYER AKTIENGESELLSCHAFT (DE) 2005-08-23 US disclosed
US-20050004207-A1 Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004207-A1 Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders F2, SERPINC1, F11 HPGD 25/4885ALDH1A1 1523/4885SMN1; SMN2 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.